CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) said it will release its fourth-quarter and full-year 2025 financial results before U.S. markets open on Thursday, February 19, 2026, setting the stage for a closely watched update from the biopharmaceutical company behind the first approved treatment for a serious form of liver disease.
Following the release, Madrigal’s management team will host a live webcast at 8 a.m. Eastern Time to review the company’s financial and operating performance. The webcast will be available through the Investor Relations section of the company’s website at https://ir.madrigalpharma.com/events-and-presentations, with a replay expected to be posted about two hours after the live event.
Madrigal is focused on developing therapies for metabolic dysfunction-associated steatohepatitis, or MASH, a progressive liver disease with limited treatment options and significant unmet medical need. The company’s lead product, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to address key drivers of the disease.
Rezdiffra is currently the first and only medication approved by both the U.S. Food and Drug Administration and the European Commission for the treatment of MASH with moderate to advanced fibrosis, classified as stages F2 to F3. Madrigal is also conducting an ongoing Phase 3 outcomes trial evaluating the therapy for compensated MASH cirrhosis, known as stage F4c.
The upcoming earnings release and management discussion are expected to provide further insight into Madrigal’s financial trajectory and the commercial rollout of Rezdiffra as the company advances its efforts in a rapidly evolving therapeutic area.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.